E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Crigler-Najjar syndrome is associated with a complete or partial hepatic deficit of bilirubin glucuronosyltransferase activity and is apparent during the neonatal period by intense jaundice. The UCD are inborn errors of metabolism that affect the transfer of nitrogen into urea. There
are 8 disorders: N-Acetylglutamate synthase deficiency, Carbamoyl phosphate synthetase I deficiency, Ornithine transcarbamylase deficiency, citrullinemia I&II, argininosuccinic aciduria, HHH syndrome & argininemia |
|
E.1.1.1 | Medical condition in easily understood language |
Liver metabolic diseases: Crigler-Najjar disease and Urea Cycle disorders |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10021601 |
E.1.2 | Term | Inborn error of metabolism NOS |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of the SAF001 long term safety follow-up study in patients having received infusions of HepaStem in a former interventional study (referred as Study A) is to document the safety of HepaStem therapy during a period up to a maximum of 48 months (4 years (Y)) in the SAF001 study (SAF001 Y1+Y2+Y3+Y4).
This long term safety follow-up study will start when the patient is ending the period of active surveillance post infusion of Hepastem in any former interventional study (Study A) conducted by PB. The safety will be assessed in terms of clinical status (physical examination, vital signs), laboratory, morphology of the liver and kidney, detection of circulating anti-HLA antibodies specific for donor cells or other immune markers related to liver diseases as well as Serious Adverse Events (SAEs) and AEs of Special Interest (AESI) related to HepaStem therapy.
|
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of the SAF001 long term safety follow-up study in patients having received infusions of HepaStem in a former interventional study (Study A) are:
- to document the long term disease evolution after having received Hepastem up to a maximum of 24 months in the SAF study (SAF001 Y1+Y2)
- to document the long term disease evolution after having received Hepastem up to a maximum of 36 months post infusion (Study A + SAF001 Y1+Y2)
- to document the long term disease evolution after having received Hepastem up to a maximum of 60 months post infusion (Study A + SAF001 Y1+Y2+Y3+Y4).
- to document the general safety during a period up to a maximum 60 months post infusion (Study A + SAF001 Y1+Y2+Y3+Y4).
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. All patients having received infusions of HepaStem during a former interventional clinical study conducted by PB and who have terminated their participation in that study.
2. For subjects under 18 years of age (16 year in UK) and for adult subjects legally incapable: the subject (if capable of signing) and parents or legal representative have provided a written informed assent/consent before enrolment or
For an adult subject legally capable: the subject has provided a written informed consent before enrolment.
|
|
E.4 | Principal exclusion criteria |
1. Subject has received mature liver cells, stem cells transplantation other than HepaStem, or organ liver transplant. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is to characterise the long term safety profile of HepaStem therapy. Assessment of safety will be achieved by evaluating the following parameters
- Physical examination
- Vital signs
- Laboratory tests
- Liver tumor markers
- Autoimmune markers related to liver pathology
- Anti-HLA antibodies specific for donor cell haplotypes
- Morphology of liver, bile ducts, and portal system by ultrasound
- Morphology of the kidneys by ultrasound
- Non-serious or serious Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs) related to HepaStem therapy.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
A 2-year assessment of both safety and disease evolution after having received Hepastem will be done by scheduling visits every 6 months (+/- 1 month) for 2 years (years 1 and 2). An additional 2-year assessment of both safety and disease evolution after having received Hepastem will be done by scheduling a yearly (+/- 1 month) visit and a mid-year (phone) interview during years 3 and 4 (+/- 1 month). |
|
E.5.2 | Secondary end point(s) |
The secondary endpoints are to characterize 1. the disease evolution after having received HepaStem therapy and 2. to report on general safety. This assessment will be based on the evaluation of:
- Report on cognitive skills, behaviour, and health-related quality of life indicators
- Non-serious or serious Adverse Events of Special Interest (AESIs) and Serious Adverse Events (SAEs) related to concomitant medications or other causes (including but not limited to tacrolimus immunosuppression therapy)
Indication I: CN
- Frequency and severity of metabolic decompensation reported as AESI
- Metabolic parameters
o Serum total bilirubin levels and serum unconjugated bilirubin levels
- Report on supportive treatment and any adjustment of:
o Phototherapy
o Medication (eg phenobarbital treatment)
Indications II: UCD
- Frequency and severity of metabolic decompensation reported as AESI
- Metabolic parameters (please refer to section 8, table 4)
o Ammonium (NH3) values
o Amino acids in plasma: Alanine, Arginine, Citrulline, Glutamine
o Urine: Orotic acid for OTC deficiency patients only; argininosuccinate acid for ASL deficiency patients only
- Report on supportive treatment and any adjustment of:
o diet (natural protein intake, total protein intake, amino acid supplements)
o Medication (eg nitrogen scavengers)
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
A 2-year assessment of both safety and disease evolution after having received Hepastem will be done by scheduling visits every 6 months (+/- 1 month) for 2 years (years 1 and 2). An additional 2-year assessment of both safety and disease evolution after having received Hepastem will be done by scheduling a yearly (+/- 1 month) visit and a mid-year (phone) interview during years 3 and 4 (+/- 1 month). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 12 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last patient, last visit. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 48 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 48 |
E.8.9.2 | In all countries concerned by the trial days | 0 |